SciSparc (SPRC)announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding ...

NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. Neurothera Labs Inc. has signed a non-binding term sheet to acquire a 55% equity ...

Researchers based in Sweden have developed a metabolism-based model of mammalian cell types commonly used in antibody production. The team, led by Veronique Chotteau, PhD, a professor at KTH Royal ...

Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

A new generative AI model trained on UK Biobank data can simultaneously forecast the risks and timing of developing over 1,000 different diseases a decade into the future. The developers applied ...

New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior End-to-end support from experimental design to ...

For monoclonal antibodies (mAbs), traditional design space identification methods typically rely on expensive wet-lab experiments or in silico models that, for low-density data, need improvement. A ...

UBC Okanagan researchers have developed a 3D bio-printed model that closely mimics the complexity of natural lung tissue, an innovation that could transform how scientists study lung disease and ...

A new kind of large language model, developed by researchers at the Allen Institute for AI (Ai2), makes it possible to control how training data is used even after a model has been built.

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...